Physiomics Plc (PYC) – Strategy, SWOT and Corporate Finance Report

Physiomics Plc (PYC) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Physiomics Plc (Physiomics) provides consulting services to pharmaceutical companies in the areas of computational biology and quantitative pharmacology. The company’s proprietary technology platform, Virtual Tumour, uses computer modeling to predict the effects of cancer drugs and treatments. Physiomics offers model-based drug development services, which include population (Pharmacokinetics and Pharmacodynamics) PKPD analysis of clinical data, back-translational analysis, and optimal design of future studies. It also has Quantitative Systems Pharmacology which involves the combination of PK/PD of a therapeutic agent with the mechanistic model and a large quantitative experimental drug data. Physiomics is headquartered in Oxfordshire, the UK.

Scope

• Detailed information on Physiomics Plc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Physiomics Plc in the form of a SWOT analysis

• An in-depth view of the business model of Physiomics Plc including a breakdown and examination of key business segments

• News about Physiomics Plc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Physiomics Plc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Physiomics Plc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Physiomics Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Elekta AB

e-Therapeutics Plc

Avacta Group Plc

Sareum Holdings Plc

Cyprotex Ltd

Elekta AB

Cyprotex Ltd

e-Therapeutics Plc

Sareum Holdings Plc

Avacta Group Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Physiomics Plc - Key Facts

Physiomics Plc - Key Employees

Physiomics Plc - Key Employee Biographies

Physiomics Plc - Major Products and Services

Physiomics Plc - History

Physiomics Plc - Company Statement

Physiomics Plc - Locations And Subsidiaries

Head Office

Section 2 – Company Analysis

Company Overview

Physiomics Plc - Business Description

Physiomics Plc - Corporate Strategy

Physiomics Plc - SWOT Analysis

SWOT Analysis - Overview

Physiomics Plc - Strengths

Physiomics Plc - Weaknesses

Physiomics Plc - Opportunities

Physiomics Plc - Threats

Physiomics Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Physiomics Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Oct 04, 2023: Physiomics Announces Change of Registered Address

Oct 03, 2023: Physiomics : Senior Management Update

Sep 04, 2023: Physiomics : Senior Management Update

Aug 31, 2023: Physiomics : Contract Award

Aug 08, 2023: Physiomic : Contract award

May 31, 2023: Physiomics Collaboration with The University of Sheffield

May 23, 2023: Physiomics plc : Trading update

Apr 26, 2023: ValiRx : Collaborative services agreement

Mar 11, 2023: Physiomics Announces Interim Results Statement for the six-month period ended 31 December 2022

Mar 07, 2023: Interim Results Statement for the six-month period ended 31 December 2022

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Physiomics Plc, Key Facts

Physiomics Plc, Key Employees

Physiomics Plc, Key Employee Biographies

Physiomics Plc, Major Products and Services

Physiomics Plc, History

Physiomics Plc, Key Competitors

Physiomics Plc, Annual Ratios

Physiomics Plc, Annual Ratios (Cont…1)

Physiomics Plc, Interim Ratios

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Physiomics Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Physiomics Plc, Performance Chart (2019 – 2023)

Physiomics Plc, Ratio Charts

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Physiomics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports